Figure 3.

A. FACS profile of LNCaP cells according to their surface TROP2 expression level. Black line: cells were stained mouse isotype control; red line: cells were stained with TROP2 antibody. B. RT-qPCR quantitation of TACSTD2 (TROP2), POU5F1 (Oct4), NKX3.1, and ALDH1A3 mRNA expression. DCLK1 was undetectable in these cells C. Percentage of viable TROP2^high, TROP2^low and ungated LNCaP cells at the end of a 5-day treatment with docetaxel alone (DTX, top) or in combination with flutamide (DTX + FLT, bottom). Data represents the mean percentage of surviving cells after exposure to the three highest concentrations of docetaxel (1nM, 10nM, 100nM). D. Percentage of viable TROP2^high, TROP2^low and ungated LNCaP cells after a 5-day treatment with docetaxel alone (DTX, top) or in combination with flutamide (DTX + FLT, bottom) followed by a 7-day recovery phase in docetaxel-free medium. Data represents the mean percentage of surviving cells after exposure to the three highest concentrations of docetaxel (1nM, 10nM, 100nM). In C and D: *, P < 0.05, **, P < 0.01, significantly different from TROP2^low cells, one-way ANOVA with Bonferroni post-hoc, n=3.